1 – 10 of 23
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
How to manage patients with germline DDX41 variants : Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms
(
- Contribution to journal › Article
-
Mark
Single-cell genomics details the maturation block in BCP-ALL and identifies therapeutic vulnerabilities in DUX4-r cases
(
- Contribution to journal › Article
-
Mark
TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition
(
- Contribution to journal › Article
- 2023
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
(
- Contribution to journal › Article
-
Mark
IL1RAP is expressed in several subtypes of pediatric acute lymphoblastic leukemia and can be used as a target to eliminate
ETV6::RUNX1-positive leukemia cells in preclinical models.
(
- Contribution to journal › Article
- 2020
-
Mark
Clonal competition within complex evolutionary hierarchies shapes AML over time
(
- Contribution to journal › Article
- 2019
-
Mark
FLT3
N676K
drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis
(
- Contribution to journal › Letter
- 2018
-
Mark
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
(
- Contribution to journal › Article
- 2017
-
Mark
Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells
(
- Contribution to journal › Article
-
Mark
Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib
(
- Contribution to journal › Article